WO2003014162A1 - ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY - Google Patents
ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY Download PDFInfo
- Publication number
- WO2003014162A1 WO2003014162A1 PCT/JP2002/007874 JP0207874W WO03014162A1 WO 2003014162 A1 WO2003014162 A1 WO 2003014162A1 JP 0207874 W JP0207874 W JP 0207874W WO 03014162 A1 WO03014162 A1 WO 03014162A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- ganglioside
- dna encoding
- protein
- amyloid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60226036.1T DE60226036T9 (de) | 2001-08-03 | 2002-08-01 | ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT |
JP2003519111A JP4729717B2 (ja) | 2001-08-03 | 2002-08-01 | GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA |
EP02755765.1A EP1420032B2 (en) | 2001-08-03 | 2002-08-01 | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
US10/768,193 US7339035B2 (en) | 2001-08-03 | 2004-02-02 | Antibody recognizing GM1 ganglioside-bound amyloid β-protein and DNA encoding the antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-235700 | 2001-08-03 | ||
JP2001235700 | 2001-08-03 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/768,193 Continuation US7339035B2 (en) | 2001-08-03 | 2004-02-02 | Antibody recognizing GM1 ganglioside-bound amyloid β-protein and DNA encoding the antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003014162A1 true WO2003014162A1 (en) | 2003-02-20 |
Family
ID=19067100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/007874 WO2003014162A1 (en) | 2001-08-03 | 2002-08-01 | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY |
Country Status (5)
Country | Link |
---|---|
US (1) | US7339035B2 (ja) |
EP (1) | EP1420032B2 (ja) |
JP (2) | JP4729717B2 (ja) |
DE (1) | DE60226036T9 (ja) |
WO (1) | WO2003014162A1 (ja) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006137354A1 (ja) * | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | アミロイド線維形成に対する阻害活性を有する抗体 |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
WO2008156621A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
US8378081B2 (en) | 2008-02-08 | 2013-02-19 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US8613924B2 (en) | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US8796439B2 (en) | 2006-07-14 | 2014-08-05 | Ac Immune S.A. | Nucleic acid molecules encoding a humanized antibody |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9090679B2 (en) | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
EP1420032B2 (en) † | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101591223B1 (ko) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
AU2008267038B2 (en) * | 2007-06-12 | 2014-08-07 | Ac Immune S.A. | Humanized antibodies to amyloid beta |
CA2701788C (en) * | 2007-10-05 | 2017-06-13 | Genentech, Inc. | Humanized beta-amyloid antibody for treating ocular diseases |
SG185316A1 (en) * | 2007-10-19 | 2012-11-29 | Immunas Pharma Inc | ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF |
US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
JP6668329B2 (ja) | 2015-03-25 | 2020-03-18 | 国立研究開発法人国立長寿医療研究センター | 新規オキサジアゾール誘導体及びこれを含有する医薬 |
CN114929274A (zh) * | 2019-10-17 | 2022-08-19 | 台湾卫生研究院 | 琥珀酸作为用于癌症诊断和治疗的生物标记的用途 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) * | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) † | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
EP1257584B2 (en) † | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
PE20020574A1 (es) † | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
JP4729717B2 (ja) † | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA |
-
2002
- 2002-08-01 JP JP2003519111A patent/JP4729717B2/ja not_active Expired - Lifetime
- 2002-08-01 EP EP02755765.1A patent/EP1420032B2/en not_active Expired - Lifetime
- 2002-08-01 DE DE60226036.1T patent/DE60226036T9/de active Active
- 2002-08-01 WO PCT/JP2002/007874 patent/WO2003014162A1/ja active IP Right Grant
-
2004
- 2004-02-02 US US10/768,193 patent/US7339035B2/en not_active Expired - Lifetime
-
2007
- 2007-10-02 JP JP2007258842A patent/JP4102850B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007861A1 (en) * | 1988-12-28 | 1990-07-26 | Protein Design Labs, Inc. | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
Non-Patent Citations (4)
Title |
---|
JONES P.T. ET AL: "Replacing the complemtentarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, no. 6069, 29 May 1986 (1986-05-29) - 4 June 1986 (1986-06-04), pages 522 - 525, XP002062670 * |
See also references of EP1420032A4 * |
YANAGISAWA K. ET AL: "Amyloid beta-protein (Abeta) associated with lipid molecules: immumoreactivity distinct from that of soluble Abeta", FEBS LETT., vol. 420, no. 1, 22 December 1997 (1997-12-22), pages 43 - 46, XP004261667 * |
YANAGISAWA K. ET AL: "GM1 ganglioside-bound amyloid beta-protein in Alzheimer's disease brain", NEUROBIOL. AGING, vol. 19, no. 1 SUPPL., January 1998 (1998-01-01) - February 1998 (1998-02-01), pages S65 - S67, XP002958913 * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1420032B2 (en) † | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
US10464976B2 (en) | 2003-01-31 | 2019-11-05 | AbbVie Deutschland GmbH & Co. KG | Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
WO2006137354A1 (ja) * | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | アミロイド線維形成に対する阻害活性を有する抗体 |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US10538581B2 (en) | 2005-11-30 | 2020-01-21 | Abbvie Inc. | Anti-Aβ globulomer 4D10 antibodies |
US10208109B2 (en) | 2005-11-30 | 2019-02-19 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US10323084B2 (en) | 2005-11-30 | 2019-06-18 | Abbvie Inc. | Monoclonal antibodies against amyloid beta protein and uses thereof |
US8796439B2 (en) | 2006-07-14 | 2014-08-05 | Ac Immune S.A. | Nucleic acid molecules encoding a humanized antibody |
US9951125B2 (en) | 2006-11-30 | 2018-04-24 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US8877190B2 (en) | 2006-11-30 | 2014-11-04 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2481408A2 (en) | 2007-03-01 | 2012-08-01 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP2527366A1 (en) * | 2007-06-12 | 2012-11-28 | AC Immune S.A. | Monoclonal anti beta amyloid antibody |
US9175094B2 (en) | 2007-06-12 | 2015-11-03 | Ac Immune S.A. | Monoclonal antibody |
WO2008156621A1 (en) * | 2007-06-12 | 2008-12-24 | Ac Immune S.A. | Monoclonal anti beta amyloid antibody |
US9585956B2 (en) | 2007-06-12 | 2017-03-07 | Ac Immune S.A. | Polynucleotides encoding anti-amyloid beta monoclonal antibodies |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US8378081B2 (en) | 2008-02-08 | 2013-02-19 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9090680B2 (en) | 2008-02-08 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to abeta oligomers and uses thereof |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US9090679B2 (en) | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
US8858949B2 (en) | 2009-08-06 | 2014-10-14 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8613924B2 (en) | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9822171B2 (en) | 2010-04-15 | 2017-11-21 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US10047121B2 (en) | 2010-08-14 | 2018-08-14 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Also Published As
Publication number | Publication date |
---|---|
EP1420032A1 (en) | 2004-05-19 |
US20040181042A1 (en) | 2004-09-16 |
EP1420032B1 (en) | 2008-04-09 |
JP4102850B2 (ja) | 2008-06-18 |
EP1420032A4 (en) | 2005-01-05 |
DE60226036D1 (de) | 2008-05-21 |
JP2008074854A (ja) | 2008-04-03 |
DE60226036T2 (de) | 2009-06-25 |
JPWO2003014162A1 (ja) | 2004-11-25 |
DE60226036T9 (de) | 2016-09-29 |
DE60226036T3 (de) | 2016-06-16 |
EP1420032B2 (en) | 2015-12-16 |
US7339035B2 (en) | 2008-03-04 |
JP4729717B2 (ja) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003014162A1 (en) | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY | |
WO2003041562A3 (en) | Molecular cancer diagnosis using tumor gene expression signature | |
WO2005062770A3 (en) | Method for conducting pharmacogenomics-based studies | |
DE60224383D1 (de) | Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen | |
WO2002074240A3 (en) | Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder | |
EP2305286A3 (en) | Treatment for Alzeimer's disease | |
WO2002077187A3 (en) | Proteins producing an altered immunogenic response and methods of making and using the same | |
WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
AU2001260140A1 (en) | Nematodes as model organisms for the investigation of neurodegenerative diseases, in particular parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene. | |
WO2005076939A3 (en) | Assay and method for diagnosing and treating alzheimer’s disease | |
WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
WO2001040291A3 (en) | Proteins and nucleic acids encoding the same | |
WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
WO2002095394A3 (de) | Verfahren zur analyse einer biologischen probe | |
ATE490979T1 (de) | Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene | |
WO2006134128A3 (en) | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases | |
WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
WO2001057535A3 (en) | Analytical method to evaluate animal models of neurofibrillary degeneration | |
AU2003224120A1 (en) | Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases | |
ATE312914T1 (de) | Rdgb-proteine | |
WO2005038463A8 (en) | Method for the detection of a neurological or psychiatric, demential disease, especially alzheimer's disease by use of cholecystokinin (cck) -molecules, corresponding substances and detection reagents | |
WO2005049790A3 (en) | Skn-1 and gsk-3 genes and proteins | |
WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003519111 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10768193 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002755765 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002755765 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002755765 Country of ref document: EP |